IONS 📈 Ionis Pharmaceuticals - Overview

Ionis Pharmaceuticals Inc is a biotechnology company that focuses on discovering and developing RNA-targeted therapeutics, primarily in the United States. The company has developed a range of treatments, including SPINRAZA, which is used to treat spinal muscular atrophy in both pediatric and adult patients. Additionally, they offer TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults, and WAYLIVRA, an antisense medicine for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy.

The company's pipeline includes several medicines in phase 3 studies, such as Eplontersen, which is being developed as a monthly self-administered subcutaneous injection to treat all types of transthyretin amyloidosis. They are also working on Olezarsen for patients with familial chylomicronemia syndrome and severe hypertriglyceridemia, as well as Donidalorsen for patients with hereditary angioedema. Furthermore, Ionis Pharmaceuticals is developing treatments for amyotrophic lateral sclerosis, including ION363, and for cardiovascular disease, such as Pelacarsen, which targets patients with established cardiovascular disease and elevated lipoprotein(a).

Ionis Pharmaceuticals has established strategic collaborations with several major pharmaceutical companies, including Biogen for the treatment of neurological disorders, and Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. These collaborations enable the company to leverage its expertise in RNA-targeted therapeutics and expand its reach into new areas. With a strong foundation in research and development, Ionis Pharmaceuticals continues to advance its pipeline of innovative treatments, addressing significant unmet medical needs.

The company, which was incorporated in 1989 and is based in Carlsbad, California, has a robust portfolio of products and pipeline candidates. Its commitment to innovation and collaboration has positioned Ionis Pharmaceuticals as a leader in the biotechnology industry, with a focus on developing groundbreaking RNA-targeted therapeutics. As a publicly traded company, Ionis Pharmaceuticals' common stock is listed on the NASDAQ stock exchange under the ticker symbol IONS, and its ISIN is US4622221004, classified under the GICS Sub Industry: Biotechnology.